Pfizer (PFE) : Net money flow in Pfizer (PFE) was negative ($28.53 million) and the inflow of money on uptick was $110.1 million, whereas, the outflow of money on downticks amounted to $138.63 million on Thursday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.79. The block trades show that the large investors, were aggressive sellers in the stock. The total value of block trades on upticks was only $11.03 million. On the other hand, the total value of block trades done on downticks was $40.34 million. The ratio of uptick to downtick block trades was 0.27. The money flow in block trades was negative ($29.31). Pfizer (PFE) gained $0.6 cent during the day and reached $36.91, a gain of 1.64% over the previous day.
The stock has recorded a 20-day Moving Average of 5.14% and the 50-Day Moving Average is 7.07%. Shares have rallied 3.82% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $36.46 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $34.86 and the 200 Day Moving Average price is recorded at $32.11.
Pfizer (NYSE:PFE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.49 and $36.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $36.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.92, notching a gain of 1.68% for the day. The total traded volume was 27,661,388 . The stock had closed at $36.31 on the previous day.
In an insider trading activity,The officer (Executive Vice President) of Pfizer Inc, Damelio Frank A sold 100,000 shares at $34.49 on May 26, 2016. The Insider selling transaction had a total value worth of $3,449,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.